Providence Therapeutics Launches Revolutionary Trial
Providence Therapeutics, based in Calgary, has announced a groundbreaking clinical trial, making strides in the battle against pediatric brain cancer. On November 18, 2026, the company initiated enrollment for the PaedNEO-VAX trial, the first-ever study utilizing personalized messenger RNA (mRNA) vaccines specifically designed for children and young adults who suffer from aggressive and resistant brain tumors.
The trial offers hope where traditional treatments have failed and is a landmark achievement for the burgeoning field of personalized medicine. As noted by Providence’s CEO, Brad Sorenson, this trial represents a major developmental phase for their PTX-108 mRNA cancer vaccine program, aiming to provide new options for a demographic often underserved in medical research.
Partnering with the Australia and New Zealand Children's Hematology/Oncology Group (ANZCHOG), this trial will extend its reach across eight pediatric hospitals in both Australia and New Zealand. Not only does this collaborative effort spotlight Providence's dedication to innovation in cancer treatment, but it also highlights a significant investment from the Australian Government’s Medical Research Future Fund, alongside support from philanthropic organizations.
Pediatric brain cancer remains a grave challenge, as it constitutes one of the highest unmet medical needs in modern healthcare. The PTX-108 vaccine is thoughtfully individualized, created based on the unique tumor antigen profile of each patient. This approach equips the vaccine with the potential to stimulate a targeted immune response, allowing the body’s defenses to effectively combat cancer cells.
Children enrolled in the trial will be those diagnosed with high-risk tumors, including relapsed or refractory high-grade gliomas, diffuse midline gliomas, medulloblastomas, and ependymomas. The initial phase of the study will focus on evaluating PTX-108’s safety and tolerability, aiming to establish a recommended dosage prior to advancing to the second phase, which could facilitate regulatory approval for broader usage.
The development of PTX-108 is not done in isolation; it utilizes insights gained from the ZERO Childhood Cancer initiative, which is noted as the largest precision medicine program for childhood cancers worldwide, comprising an extensive database of whole genome sequencing data. This connection strengthens the study, merging robust data analytics with innovative treatment strategies.
QIMR Berghofer’s Director and CEO, Brandon Wainwright, underscores the imperative of moving forward with personalized mRNA treatments for pediatric patients lacking effective alternative therapies. He expressed enthusiasm for the collaboration between ANZCHOG and Providence Therapeutics, which seeks to harness their vaccine platform to benefit children facing various forms of brain cancer.
Incorporated in 2015, Providence Therapeutics operates with a focus on advancing its cutting-edge mRNA and INTENT™ lipid nanoparticle (LNP) technologies, which are designed to enhance anti-tumor responses. The company is actively expanding its applications in oncology while exploring opportunities in infectious diseases and gene editing. This new trial marks a bold stride not just for the organization, but for the entire healthcare community aimed at addressing life-threatening conditions in children.
For more information about this innovative therapeutic avenue, you can visit
Providence Therapeutics.